Skip to main content
. 2016 Jan 24;7(8):9084–9101. doi: 10.18632/oncotarget.7000

Figure 2. Kaplan-Meier survival curves for overall survival and disease-free survival stratified by the status of SF mutations in total 363 AML patients (A and B), 229 patients with intermediate-risk cytogenetics (C and D) and 161 patients with normal karyotype (E and F) who received standard intensive chemotherapy.

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2